Algaba F
Fundació Puigvert, Universitat Autònoma de Barcelona, Spain.
Eur Urol. 1999;35(5-6):496-7. doi: 10.1159/000019886.
The discovery of high-grade prostatic intraepithelial neoplasia (HGPIN) in prostatic needle biopsies is of clinical importance. Previous studies have shown prostate cancer to develop in 27-100% (average 55%) of the cases after HGPIN was diagnosed. Our preliminary findings in a Mediterranean population (Barcelona, Spain) revealed a prevalence of HGPIN of 4.4%, and an incidence of prostate cancer of 28.7% in cases in whom isolated HGPIN was identified at the first biopsy. The majority (64%) of these cases were diagnosed at the first biopsy after HGPIN diagnosis, and 52% within the first year. HGPIN persisted in 46.6% of the cases. The total mean serum prostate-specific antigen (PSA) was 9.9 +/- 6.6 ng/ml in the prostate cancer cases, compared with 8.8 +/- 7.5 in the cases without cancer. The low incidence of isolated HGPIN and subsequent cancer occurrence may be due to local factors or insufficient follow-up.
在前列腺穿刺活检中发现高级别前列腺上皮内瘤变（HGPIN）具有临床重要性。先前的研究表明，在诊断出HGPIN后，27% - 100%（平均55%）的病例会发展为前列腺癌。我们在一个地中海人群（西班牙巴塞罗那）中的初步研究结果显示，HGPIN的患病率为4.4%，在首次活检时发现孤立性HGPIN的病例中，前列腺癌的发病率为28.7%。这些病例中的大多数（64%）在诊断出HGPIN后的首次活检时被诊断出前列腺癌，52%在第一年内被诊断出。46.6%的病例中HGPIN持续存在。前列腺癌病例的总平均血清前列腺特异性抗原（PSA）为9.9 +/- 6.6 ng/ml，而无癌病例为8.8 +/- 7.5 ng/ml。孤立性HGPIN及随后癌症发生的低发生率可能是由于局部因素或随访不足。
